Loss of DNA mismatch repair in acquired resistance to cisplatin.

PubWeight™: 2.37‹?› | Rank: Top 2%

🔗 View Article (PMID 8674066)

Published in Cancer Res on July 01, 1996

Authors

S Aebi1, B Kurdi-Haidar, R Gordon, B Cenni, H Zheng, D Fink, R D Christen, C R Boland, M Koi, R Fishel, S B Howell

Author Affiliations

1: Department of Medicine and the Cancer Center, University of California at San Diego, La Jolla 92093-0812, USA.

Articles citing this

Microsatellite instability in colorectal cancer. Gastroenterology (2010) 7.39

Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev (2006) 5.08

Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet (2009) 3.99

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol (2010) 3.54

Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids (2010) 1.82

Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems. Mol Cell Biol (1997) 1.79

Carcinogen-specific induction of genetic instability. Proc Natl Acad Sci U S A (2001) 1.76

The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. Fam Cancer (2007) 1.76

Systems biology of cisplatin resistance: past, present and future. Cell Death Dis (2014) 1.74

hMutSalpha- and hMutLalpha-dependent phosphorylation of p53 in response to DNA methylator damage. Proc Natl Acad Sci U S A (1999) 1.63

Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol (2010) 1.62

Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci U S A (2003) 1.47

Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts. Nucleic Acids Res (1997) 1.38

Hijacking of the mismatch repair system to cause CAG expansion and cell death in neurodegenerative disease. DNA Repair (Amst) (2008) 1.37

Catalysis of DNA cleavage and nucleoside triphosphate synthesis by NM23-H2/NDP kinase share an active site that implies a DNA repair function. Proc Natl Acad Sci U S A (2000) 1.33

Mismatch repair proteins are activators of toxic responses to chromium-DNA damage. Mol Cell Biol (2005) 1.32

The role of mismatch repair in the prevention of base pair mutations in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1998) 1.29

Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. Proc Natl Acad Sci U S A (1998) 1.24

Multiple biochemical activities of NM23/NDP kinase in gene regulation. J Bioenerg Biomembr (2003) 1.23

Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic Acids Res (1997) 1.22

hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis. J Biol Chem (2011) 1.21

Rapid DNA double-strand breaks resulting from processing of Cr-DNA cross-links by both MutS dimers. Cancer Res (2009) 1.21

Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2. Mol Biol Cell (2005) 1.19

Extensive molecular screening for hereditary non-polyposis colorectal cancer. Br J Cancer (2000) 1.15

Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clin Cancer Res (2008) 1.09

Recognition of DNA alterations by the mismatch repair system. Biochem J (1999) 1.08

Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer (2006) 1.07

MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics (2011) 1.06

Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer (1999) 1.03

A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br J Cancer (2001) 1.02

MSH2 is essential for the preservation of genome integrity and prevents homeologous recombination in the moss Physcomitrella patens. Nucleic Acids Res (2006) 1.01

Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomark (2006) 1.01

Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics. J Mol Biol (2007) 0.99

DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation. Cancer Res (2011) 0.98

Functional and physical interaction between the mismatch repair and FA-BRCA pathways. Hum Mol Genet (2011) 0.97

A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer. Cancer (2008) 0.96

Prognosis in DNA mismatch repair deficient colorectal cancer: are all MSI tumours equivalent? Fam Cancer (2004) 0.96

The history of Lynch syndrome. Fam Cancer (2013) 0.94

The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis (2006) 0.94

Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance. Cancer Biol Ther (2008) 0.92

Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. Br J Cancer (2009) 0.92

miR-34 and p53: New Insights into a Complex Functional Relationship. PLoS One (2015) 0.91

Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link. Biochemistry (2007) 0.91

Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer. Gynecol Oncol (2010) 0.91

Parameters of Reserpine Analogs That Induce MSH2/MSH6-Dependent Cytotoxic Response. J Nucleic Acids (2010) 0.90

Determining the functional significance of mismatch repair gene missense variants using biochemical and cellular assays. Hered Cancer Clin Pract (2012) 0.89

Silencing of the DNA mismatch repair gene MLH1 induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1. Cell Rep (2014) 0.88

Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. Mol Pathol (2003) 0.87

Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. Br J Cancer (1999) 0.87

Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology (1998) 0.86

Integrin αV modulates the cellular pharmacology of copper and cisplatin by regulating expression of the influx transporter CTR1. Oncoscience (2014) 0.86

MSH2 missense mutations alter cisplatin cytotoxicity and promote cisplatin-induced genome instability. Nucleic Acids Res (2005) 0.86

Ligand modulation of a dinuclear platinum compound leads to mechanistic differences in cell cycle progression and arrest. Biochem Pharmacol (2013) 0.86

MutS homologue hMSH5: role in cisplatin-induced DNA damage response. Mol Cancer (2012) 0.85

Molecular signaling mechanisms of apoptosis in hereditary non-polyposis colorectal cancer. World J Gastrointest Pathophysiol (2012) 0.84

Allelic imbalance at p53 and microsatellite instability are predictive markers for resistance to chemotherapy in gastric carcinoma. Ann Surg Oncol (2009) 0.84

Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity. Nucleic Acids Res (2013) 0.84

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin. BMC Cancer (2005) 0.84

The mismatch repair system modulates curcumin sensitivity through induction of DNA strand breaks and activation of G2-M checkpoint. Mol Cancer Ther (2010) 0.83

Accelerated growth of intestinal tumours after radiation exposure in Mlh1-knockout mice: evaluation of the late effect of radiation on a mouse model of HNPCC. Int J Exp Pathol (2006) 0.83

Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin. Br J Cancer (1999) 0.82

Microsatellite instability in colorectal cancer. Radiol Oncol (2011) 0.82

Ku86 autoantigen related protein-1 transcription initiates from a CpG island and is induced by p53 through a nearby p53 response element. Nucleic Acids Res (2002) 0.82

Mismatch repair defects and Lynch syndrome: The role of the basic scientist in the battle against cancer. DNA Repair (Amst) (2015) 0.82

Inter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair research. DNA Repair (Amst) (2014) 0.81

MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition. Br J Cancer (2009) 0.81

DNA-Destabilizing Agents as an Alternative Approach for Targeting DNA: Mechanisms of Action and Cellular Consequences. J Nucleic Acids (2010) 0.81

Features of ovarian cancer in Lynch syndrome (Review). Mol Clin Oncol (2014) 0.80

Proteasome inhibition rescues clinically significant unstable variants of the mismatch repair protein Msh2. Proc Natl Acad Sci U S A (2012) 0.80

Genetic and epigenetic changes in human prostate cancer. Iran Red Crescent Med J (2011) 0.79

Flanking bases influence the nature of DNA distortion by platinum 1,2-intrastrand (GG) cross-links. PLoS One (2011) 0.79

Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome. Oncotarget (2016) 0.78

Photodynamic therapy of DNA mismatch repair-deficient and -proficient tumour cells. Br J Cancer (2002) 0.78

Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2. Br J Cancer (2002) 0.78

The "comparative growth assay": examining the interplay of anti-cancer agents with cells carrying single gene alterations. Neoplasia (1999) 0.78

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. J Exp Clin Cancer Res (2013) 0.78

A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity. Curr Genomics (2016) 0.78

Protein Recognition in Drug-Induced DNA Alkylation: When the Moonlight Protein GAPDH Meets S23906-1/DNA Minor Groove Adducts. Int J Mol Sci (2015) 0.77

Low frequency of replication errors in primary nervous system tumours. J Neurol Neurosurg Psychiatry (2000) 0.77

hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer. Br J Cancer (1999) 0.77

YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors. Mol Cancer Res (2015) 0.77

Drug resistance and DNA repair in leukaemia. Cytotechnology (1998) 0.76

Antitumor Activity of a 5-Hydroxy-1H-Pyrrol-2-(5H)-One-Based Synthetic Small Molecule In Vitro and In Vivo. PLoS One (2015) 0.76

Apoptosis-related mRNA expression profiles of ovarian cancer cell lines following cisplatin treatment. J Gynecol Oncol (2010) 0.76

A specific mode of microsatellite instability is a crucial biomarker in adult T-cell leukaemia/lymphoma patients. J Cancer Res Clin Oncol (2016) 0.75

Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget (2017) 0.75

Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells. PLoS One (2017) 0.75

Long-term results of definitive concurrent chemoradiotherapy using paclitaxel plus oxaliplatin in unresectable locally advanced esophageal cancer: a prospective phase II trial. Cancer Med (2016) 0.75

Renoprotective effects of antioxidants against cisplatin nephrotoxicity. J Nephropharmacol (2014) 0.75

Common Chemical Inductors of Replication Stress:  Focus on Cell-Based Studies. Biomolecules (2017) 0.75

Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Curr Med Chem (2016) 0.75

Articles by these authors

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care (1997) 23.95

Algebraic reconstruction techniques (ART) for three-dimensional electron microscopy and x-ray photography. J Theor Biol (1970) 6.86

Sporadic cases of hemorrhagic colitis associated with Escherichia coli O157:H7. Clinical, epidemiologic, and bacteriologic features. Ann Intern Med (1984) 6.54

Epitaxial BiFeO3 multiferroic thin film heterostructures. Science (2003) 6.14

A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst (1997) 5.68

Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon. J Virol (2000) 5.44

Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2+ channels. Cell (2000) 5.08

Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes. Proc Natl Acad Sci U S A (2001) 4.93

Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res (1997) 4.61

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron (2001) 4.42

Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet (2009) 3.99

Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc Natl Acad Sci U S A (2000) 3.95

Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology (1993) 3.76

Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res (1994) 3.63

hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci U S A (1996) 3.60

Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell (1999) 3.58

Conversion of diploidy to haploidy. Nature (2000) 3.28

Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature (1997) 3.14

Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06

Genomic DNA microextraction: a method to screen numerous samples. Anal Biochem (1992) 3.05

A multifactorial system for equitable selection of cadaver kidney recipients. JAMA (1987) 3.01

Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Dev (1999) 2.90

The role of interferon in influenza virus tissue tropism. J Virol (1998) 2.88

DNA repair and colorectal cancer. Gastroenterol Clin North Am (1996) 2.88

The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88

hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched DNA. Mol Cell (1999) 2.85

UNC-40, a C. elegans homolog of DCC (Deleted in Colorectal Cancer), is required in motile cells responding to UNC-6 netrin cues. Cell (1996) 2.78

Recommendations of the German Association of Urogynecology on functional sonography of the lower female urinary tract. Int Urogynecol J Pelvic Floor Dysfunct (1996) 2.78

Different training procedures recruit either one or two critical periods for contextual memory consolidation, each of which requires protein synthesis and PKA. Learn Mem (1999) 2.72

Successful eradication of sexually transmitted diseases in the People's Republic of China: implications for the 21st century. J Infect Dis (1996) 2.72

Recombinant Newcastle disease virus as a vaccine vector. J Virol (2001) 2.67

The human mismatch recognition complex hMSH2-hMSH6 functions as a novel molecular switch. Cell (1997) 2.64

Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst (1995) 2.62

A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res (1999) 2.50

The role of DNA mismatch repair in drug resistance. Clin Cancer Res (1998) 2.49

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

Negative-strand RNA viruses: genetic engineering and applications. Proc Natl Acad Sci U S A (1996) 2.47

Hoxb-4 (Hox-2.6) mutant mice show homeotic transformation of a cervical vertebra and defects in the closure of the sternal rudiments. Cell (1993) 2.45

Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells (1990) 2.43

Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene (2011) 2.36

Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol (1999) 2.29

Clinical course after liver transplantation in patients with sarcoidosis. Ann Intern Med (1993) 2.29

BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer (2003) 2.26

CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol (2001) 2.21

Interactions in the error-prone postreplication repair proteins hREV1, hREV3, and hREV7. J Biol Chem (2001) 2.19

Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res (1995) 2.17

Alterations in human colonic mucin occurring with cellular differentiation and malignant transformation. Proc Natl Acad Sci U S A (1982) 2.17

Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. A randomized, controlled trial. Ann Intern Med (1997) 2.17

Morphometric and electron-microscopic analyses of the effects of gonadotropin-releasing hormone agonists on uterine leiomyomas. Arch Pathol Lab Med (1998) 2.11

Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer (1993) 2.10

One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10

BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell (2001) 2.09

A human REV7 homolog that interacts with the polymerase zeta catalytic subunit hREV3 and the spindle assembly checkpoint protein hMAD2. J Biol Chem (2000) 2.08

JC virus DNA is present in the mucosa of the human colon and in colorectal cancers. Proc Natl Acad Sci U S A (1999) 2.08

Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res (2000) 2.04

Nodal quasiparticle in pseudogapped colossal magnetoresistive manganites. Nature (2005) 2.04

UNC-73 activates the Rac GTPase and is required for cell and growth cone migrations in C. elegans. Cell (1998) 2.02

Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis. Proc Natl Acad Sci U S A (2001) 2.00

Increased hypermutation at G and C nucleotides in immunoglobulin variable genes from mice deficient in the MSH2 mismatch repair protein. J Exp Med (1998) 2.00

Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res (1997) 1.96

Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J Biol Chem (1999) 1.96

Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum. Gut (2000) 1.95

Effect of endotoxin in IL-1 beta-deficient mice. J Immunol (1996) 1.92

Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. Gastroenterology (1998) 1.90

Micromethods for induction and assay of mouse mixed lymphocyte reactions and cytotoxicity. Eur J Immunol (1976) 1.90

Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience (1999) 1.88

Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene (1994) 1.88

Presenilin 1 negatively regulates beta-catenin/T cell factor/lymphoid enhancer factor-1 signaling independently of beta-amyloid precursor protein and notch processing. J Cell Biol (2001) 1.86

Prospective, multi-centre clinic-based evaluation of four rapid diagnostic tests for syphilis. Sex Transm Infect (2006) 1.84

Randomised clinical trial: an assessment of acupuncture on specific meridian or specific acupoint vs. sham acupuncture for treating functional dyspepsia. Aliment Pharmacol Ther (2012) 1.83

p-Chlorophenylalanine-induced chemical manifestations of phenylketonuria in rats. Science (1967) 1.82

Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice. Neurobiol Aging (1998) 1.81

BICAV: a block-iterative parallel algorithm for sparse systems with pixel-related weighting. IEEE Trans Med Imaging (2001) 1.79

AtVPS45 complex formation at the trans-Golgi network. Mol Biol Cell (2000) 1.78

Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein. Mol Cell Biol (1991) 1.77

Involvement of nucleotide excision repair in a recombination-independent and error-prone pathway of DNA interstrand cross-link repair. Mol Cell Biol (2001) 1.76

Pioneer axon guidance by UNC-129, a C. elegans TGF-beta. Science (1998) 1.76

Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat (2009) 1.75

Presenilin-1 forms complexes with the cadherin/catenin cell-cell adhesion system and is recruited to intercellular and synaptic contacts. Mol Cell (1999) 1.74

Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res (1996) 1.74

Transcription-coupled repair deficiency and mutations in human mismatch repair genes. Science (1996) 1.73

Repeated embolism and multiple aneurysms: central nervous system manifestations of cardiac myxoma. Eur J Neurol (2008) 1.72

Female embryonic lethality in mice nullizygous for both Msh2 and p53. Nat Genet (1997) 1.71

Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res (2001) 1.70

JC virus DNA sequences are frequently present in the human upper and lower gastrointestinal tract. Gastroenterology (2000) 1.68

CT in patients with scirrhous carcinoma of the GI tract: imaging findings and value for tumor detection and staging. AJR Am J Roentgenol (1995) 1.68

Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells. Eur J Cancer Clin Oncol (1989) 1.68

Steady-state regulation of the human DNA mismatch repair system. J Biol Chem (2000) 1.66

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther (2001) 1.65

Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates Abeta1-42/43 expression. Neuron (1998) 1.64

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther (1999) 1.63

Comparison of beta-adrenergic agents delivered by nebulizer vs metered dose inhaler with InspirEase in hospitalized asthmatic patients. Chest (1988) 1.62